ALIVUSPharmaceuticals
Alivus Life Sciences Limited — Profit & Loss Statement
₹980.80
-0.40%
Alivus Life Sciences Limited Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.14 Cr | -0.19 Cr | — |
| Tax Rate For Calcs | 0.26 | 0.25 | 0.26 | 0.26 | — |
| Normalized EBITDA | 717.15 Cr | 686.29 Cr | 671.81 Cr | 631.51 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 485.63 Cr | 470.89 Cr | 466.96 Cr | 418.72 Cr | — |
| Reconciled Depreciation | 60.61 Cr | 53.45 Cr | 42.09 Cr | 37.88 Cr | — |
| Reconciled Cost Of Revenue | 1.08K Cr | 1.00K Cr | 1.03K Cr | 1.06K Cr | — |
| EBITDA | 717.15 Cr | 686.29 Cr | 671.25 Cr | 630.76 Cr | — |
| EBIT | 656.54 Cr | 632.84 Cr | 629.16 Cr | 592.89 Cr | — |
| Net Interest Income | -2.41 Cr | -1.55 Cr | 15.22 Cr | -21.18 Cr | — |
| Interest Expense | 2.41 Cr | 1.55 Cr | 0.55 Cr | 27.96 Cr | — |
| Normalized Income | 485.63 Cr | 470.89 Cr | 467.38 Cr | 419.27 Cr | — |
| Net Income From Continuing And Discontinued Operation | 485.63 Cr | 470.89 Cr | 466.96 Cr | 418.72 Cr | — |
| Total Expenses | 1.76K Cr | 1.66K Cr | 1.45K Cr | 1.51K Cr | — |
| Diluted Average Shares | 12.29 Cr | 12.27 Cr | 12.25 Cr | 11.75 Cr | — |
| Basic Average Shares | 12.25 Cr | 12.25 Cr | 12.25 Cr | 11.75 Cr | — |
| Diluted EPS | 39.52 | 38.38 | 38.11 | 35.63 | — |
| Basic EPS | 39.63 | 38.43 | 38.11 | 35.63 | — |
| Diluted NI Availto Com Stockholders | 485.63 Cr | 470.89 Cr | 466.96 Cr | 418.72 Cr | — |
| Net Income Common Stockholders | 485.63 Cr | 470.89 Cr | 466.96 Cr | 418.72 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 485.63 Cr | 470.89 Cr | 466.96 Cr | 418.72 Cr | — |
| Net Income Including Noncontrolling Interests | 485.63 Cr | 470.89 Cr | 466.96 Cr | 418.72 Cr | — |
| Net Income Continuous Operations | 485.63 Cr | 470.89 Cr | 466.96 Cr | 418.72 Cr | — |
| Tax Provision | 168.50 Cr | 160.40 Cr | 161.65 Cr | 146.20 Cr | — |
| Pretax Income | 654.13 Cr | 631.29 Cr | 628.61 Cr | 564.92 Cr | — |
| Other Non Operating Income Expenses | 34.57 Cr | 12.04 Cr | 0.17 Cr | 0.32 Cr | — |
| Net Non Operating Interest Income Expense | -2.41 Cr | -1.55 Cr | 15.22 Cr | -21.18 Cr | — |
| Interest Expense Non Operating | 2.41 Cr | 1.55 Cr | 0.55 Cr | 27.96 Cr | — |
| Operating Income | 621.98 Cr | 620.79 Cr | 600.76 Cr | 578.93 Cr | — |
| Operating Expense | 684.06 Cr | 660.41 Cr | 415.74 Cr | 450.82 Cr | — |
| Other Operating Expenses | 371.75 Cr | 348.80 Cr | 215.47 Cr | 187.51 Cr | — |
| Depreciation And Amortization In Income Statement | 60.61 Cr | 53.45 Cr | 42.09 Cr | 37.88 Cr | — |
| Depreciation Income Statement | 60.61 Cr | 53.45 Cr | 40.65 Cr | 37.88 Cr | — |
| Gross Profit | 1.31K Cr | 1.28K Cr | 1.02K Cr | 1.03K Cr | — |
| Cost Of Revenue | 1.08K Cr | 1.00K Cr | 1.03K Cr | 1.06K Cr | — |
| Total Revenue | 2.39K Cr | 2.28K Cr | 2.05K Cr | 2.09K Cr | — |
| Operating Revenue | 2.39K Cr | 2.28K Cr | 2.05K Cr | 2.09K Cr | — |
| Total Unusual Items | — | -0.70 Cr | -0.56 Cr | -0.74 Cr | -0.58 Cr |
| Total Unusual Items Excluding Goodwill | — | -0.70 Cr | -0.56 Cr | -0.74 Cr | -0.58 Cr |
| Interest Income | — | 12.02 Cr | 15.77 Cr | 6.78 Cr | 0.43 Cr |
| Rent Expense Supplemental | — | 0.38 Cr | 0.42 Cr | 0.22 Cr | 0.16 Cr |
| Special Income Charges | — | -0.70 Cr | -0.56 Cr | -0.74 Cr | -0.58 Cr |
| Other Special Charges | — | 0.70 Cr | 0.56 Cr | 0.74 Cr | 0.58 Cr |
| Interest Income Non Operating | — | 12.02 Cr | 15.77 Cr | 6.78 Cr | 0.43 Cr |
| Amortization | — | 3.67 Cr | 1.45 Cr | — | — |
| Selling General And Administration | — | 39.56 Cr | 33.77 Cr | 30.98 Cr | 41.28 Cr |
| Selling And Marketing Expense | — | 24.04 Cr | 24.62 Cr | 22.83 Cr | 33.79 Cr |
| General And Administrative Expense | — | 15.52 Cr | 9.15 Cr | 8.15 Cr | 7.50 Cr |
| Rent And Landing Fees | — | 0.38 Cr | 0.42 Cr | 0.22 Cr | 0.16 Cr |
| Research And Development | — | — | — | 0.00 | 0.29 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Alivus Life Sciences Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.